Marta Kijanka, PhD, | Interim Chief Executive Officer
Marta Kijanka (1985; PhD) is a medical biotechnologist by training. In 2010 she joined the Molecular Oncology Group at Utrecht University to work on a project focusing on cancer molecular imaging and therapy using antibody fragments. Marta joined APO-T in August 2015 as VP of R&D. Since January 2018 she acts as interim CEO devoting her time to the overall strategy and general management of APO-T.